

Funder	Project Title	Funding	Institution
Autism Speaks	Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine	\$44,917	The Ohio State University
National Institutes of Health	Pharmacogenomics in autism treatment	\$83,961	University of California, Davis
National Institutes of Health	Pharmacogenomics in autism treatment	\$121,239	University of California, Davis
National Institutes of Health	Targeted pharmacologic interventions for autism	\$355,516	Indiana University-Purdue University Indianapolis
National Institutes of Health	Pharmacotherapy of pervasive developmental disorders	\$184,259	Indiana University-Purdue University Indianapolis
National Institutes of Health	Open label risperidone in children and adolescents with autistic disorder	\$244	Mount Sinai School of Medicine
National Institutes of Health	ADHD symptoms in autism: Cognition, behavior, treatment	\$271,086	University of Texas Health Science Center at Houston